title: Immunosuppressive therapy for patients with refractory anemia.
abstract: Trials of immunosuppressive therapy have been reported in some case reports of hypoplastic myelodysplastic syndrome (MDS). In this study, we gave immunosuppressive therapies to eight patients with normo- or hyperplastic MDS of refractory anemia subtype without karyotypic abnormalities and analyzed the HLA-DRB1 type or the presence of paroxysmal nocturnal hemoglobinuria (PNH) neutrophils in these patients. Cyclosporin A (CyA) therapy was effective for improving cytopenia in four of the eight MDS patients. While the side effects of CyA were mostly mild and transient, one patient demonstrated karyotypic abnormality following CyA therapy and accelerated to refractory anemia with an excess of blasts. Additional antithymocyte globulin (ATG) therapy was effective in one of three nonresponders to CyA therapy. One patient died due to leukemic transformation after ATG therapy. When we analyzed the correlation between the response to CyA therapy and the HLA-DRB1 type, there were more responders with DRB1*1501 (three of four patients) than without (one of four patients), but a statistically significant difference was not evident between the two groups. In addition, the presence of PNH neutrophils was not correlated with the response to CyA and/or ATG therapy. These results indicate the usefulness of immunosuppressive therapies even for normo- or hyperplastic MDS patients. Further trials using more patients with a long follow-up period would be worthwhile in order to clarify the possibility of disease progression and in order to predict the response of patients.
authors.affiliation: Chihaya Hospital, Fukuoka, Japan. asanobu@crux.ocn.ne.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Asano
authors.forename: M
authors.initials: M
authors.lastname: Maeda
authors.forename: N
authors.initials: N
authors.lastname: Uchida
authors.forename: T
authors.initials: T
authors.lastname: Yokoyama
authors.forename: K
authors.initials: K
authors.lastname: Osaki
authors.forename: K
authors.initials: K
authors.lastname: Shimoda
authors.forename: H
authors.initials: H
authors.lastname: Gondo
authors.forename: T
authors.initials: T
authors.lastname: Okamura
authors.forename: S
authors.initials: S
authors.lastname: Okamura
authors.forename: Y
authors.initials: Y
authors.lastname: Niho
mesh_terms: D000328:Adult; D000368:Aged; D000753:Anemia, Refractory / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006684:HLA-DR Antigens / Q000032:analysis; D059811:HLA-DRB1 Chains; D006457:Hemoglobinuria, Paroxysmal / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009504:Neutrophils; D016896:Treatment Outcome
chemical_list: D000961:Antilymphocyte Serum; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; D007166:Immunosuppressive Agents; D016572:Cyclosporine